Minkyung Park, M.D.

Medical School

Jacobs School of Medicine & Biomedical Sciences at University of Buffalo (2010)

Internship

Johns Hopkins Hospital (2011), Psychiatry

Residency

Johns Hopkins Hospital (2014), Psychiatry

Fellowship

National Institute of Mental Health (2016), Clinical Research

Featured Publications

Clinical Trial of the Potassium Channel Activator Diazoxide for Major Depressive Disorder Halted Due to Intolerability.

Kadriu B, Yuan S, Farmer C, Nugent AC, Lener MS, Niciu MJ, Park M, Yazdian A, Ballard ED, Henn FA, Henter ID, Park LT, Zarate CA J Clin Psychopharmacol 2018 Mar

The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder.

Niciu MJ, Iadarola ND, Banerjee D, Luckenbaugh DA, Park M, Lener M, Park L, Ionescu DF, Ballard ED, Brutsche NE, Akula N, McMahon FJ, Machado-Vieira R, Nugent AC, Zarate CA J. Psychopharmacol. (Oxford) 2017 Oct 269881117732514

Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine.

Lener MS, Niciu MJ, Ballard ED, Park M, Park LT, Nugent AC, Zarate CA Biol. Psychiatry 2017 May 81 10 886-897

Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression.

Park M, Newman LE, Gold PW, Luckenbaugh DA, Yuan P, Machado-Vieira R, Zarate CA, J Psychiatr Res 2017 01 84 113-118

THERAPEUTIC MODULATION OF GLUTAMATE RECEPTORS IN MAJOR DEPRESSIVE DISORDER.

Jaso BA, Niciu MJ, Iadarola ND, Lally N, Richards EM, Park M, Ballard ED, Nugent AC, Machado-Vieira R, Zarate CA Curr Neuropharmacol 2016 Mar

• American Society of Clinical Psychopharmacology Clinical Trials Workshop Travel Award
  (2016)
• National Institute of Mental Health Clinical Research Training
  (2014)
• Gold Humanism Award
  (2009)

• American Society of Clinical Psychopharmacology (2016)